BridgeBio Pharma
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade BridgeBio Pharma 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BBIO
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development.
CEONeil Kumar
CEONeil Kumar
Employees730
Employees730
HeadquartersPalo Alto, California
HeadquartersPalo Alto, California
Founded2015
Founded2015
Employees730
Employees730
BBIO Key Statistics
Market cap13.88B
Market cap13.88B
Price-Earnings ratio-17.20
Price-Earnings ratio-17.20
Dividend yield—
Dividend yield—
Average volume2.23M
Average volume2.23M
High today$72.49
High today$72.49
Low today$70.93
Low today$70.93
Open price$71.14
Open price$71.14
Volume524.47K
Volume524.47K
52 Week high$72.49
52 Week high$72.49
52 Week low$25.34
52 Week low$25.34
Stock Snapshot
The current BridgeBio Pharma(BBIO) stock price is $72.49, with a market capitalization of 13.88B. The stock trades at a price-to-earnings (P/E) ratio of -17.20.
During the trading session on 2025-12-01, BridgeBio Pharma(BBIO) shares reached a daily high of $72.49 and a low of $70.93. At a current price of $72.49, the stock is +2.2% higher than the low and still 0.0% under the high.
Trading volume for BridgeBio Pharma(BBIO) stock has reached 524.47K, versus its average volume of 2.23M.
Over the past 52 weeks, BridgeBio Pharma(BBIO) stock has traded between a high of $72.49 and a low of $25.34.
Over the past 52 weeks, BridgeBio Pharma(BBIO) stock has traded between a high of $72.49 and a low of $25.34.
Analyst ratings
90%
of 20 ratingsBuy
90%
Hold
10%
Sell
0%
People also own
Based on the portfolios of people who own BBIO. This list is generated using Robinhood data, and it’s not a recommendation.